KPV has laboratory and cell-based evidence, including work in human cells, but we did not identify established human drug-treatment trials. Claims about gut, skin or anti-inflammatory benefit in people therefore remain unproven.
Still uncertain: Whether it benefits people, human dose, how the body handles it, route-specific benefit or long-term safety.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Alpha-MSH-derived tripeptide
Entity type
Peptide
Research focus
Inflammation, gut, skin and wound biology
Human evidence
FDA reports no identified human drug-product exposure to KPV by any route. Human-derived keratinocyte studies are in vitro and do not constitute clinical exposure.
Regulatory status
Not FDA-approved; FDA highlights lack of human exposure and safety data.
Main limitations
Clinical efficacy, human dose, pharmacokinetics, route-specific benefit or long-term safety.
Safety
Human safety, immunogenicity and product-quality risks are not adequately characterised.
Evidence reviewed
2026-09-18
i
FDA reports no identified human drug-product exposure to KPV by any route. Human-derived keratinocyte studies are in vitro and do not constitute clinical exposure.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Human safety, immunogenicity and product-quality risks are not adequately characterised.
Human therapeutic safety, immunogenicity and product-quality risks are not adequately characterised.
Technical details
Mechanism / biologyC-terminal tripeptide of alpha-MSH studied for melanocortin-independent anti-inflammatory activity.
Route / formulation boundaryTopical, oral and injectable claims should be separated because route changes exposure and risk.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceStudy-regimen evidence reviewed. No verified human drug-exposure regimen identified; human-cell and preclinical concentrations are not human dosing evidence.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
1outcome records
5linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
